Information Provided By:
Fly News Breaks for July 31, 2019
Jul 31, 2019 | 11:41 EDT
After Chimerix announced the acquisition from privately-held Cantex Pharmaceuticals of exclusive worldwide rights to develop and commercialize CX-01, H.C. Wainwright analyst Edward White noted that "impressive data" from a Phase 2b trial of CX-01 in combination with chemotherapy was reported at this year's ASCO meeting. White has a Buy rating and $5 price target on Chimerix shares.
News For CMRX From the Last 2 Days
There are no results for your query CMRX